Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Please always quote using this URN: urn:nbn:de:bvb:20-opus-121340
  • Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxisInvasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Sabine Mousset, Dieter Buchheidt, Werner Heinz, Markus Ruhnke, Oliver A. Cornely, Gerlinde Egerer, William Krüger, Hartmut Link, Silke Neumann, Helmut Ostermann, Jens Panse, Olaf Penack, Christina Rieger, Martin Schmidt-Hieber, Gerda Silling, Thomas Südhoff, Andrew J. Ullmann, Hans-Heinrich Wolf, Georg Maschmeyer, Angelika Böhme
URN:urn:nbn:de:bvb:20-opus-121340
Document Type:Journal article
Faculties:Medizinische Fakultät / Medizinische Klinik und Poliklinik II
Language:English
Parent Title (English):Annals of Hematology
Year of Completion:2014
Volume:96
Pagenumber:13-32
Source:Annals of Hematology (2014) 93:13–32 DOI 10.1007/s00277-013-1867-1
DOI:https://doi.org/10.1007/s00277-013-1867-1
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=24026426
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:antifungal agents; antifungals; aspergillosis; cancer; hematologic malignancies; invasive candidiasis; invasive fungal infections; mycoses
Release Date:2016/02/18
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung